What is citicoline, including its indications, dosing regimens, and safety profile?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 22, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Citicoline Overview

Citicoline should not be used for acute ischemic stroke based on the definitive failure of the large ICTUS trial, though it may have limited benefit in glaucoma and mild cognitive impairment where evidence is more supportive. 1

What is Citicoline?

Citicoline (CDP-choline) is a phospholipid precursor that serves as an intermediary in phosphatidylcholine synthesis, a critical component of neuronal cell membranes. The compound undergoes rapid hydrolysis after administration into cytidine and choline, which cross the blood-brain barrier separately and are resynthesized into CDP-choline within brain cells 2.

Mechanism of Action

The proposed neuroprotective mechanisms include:

  • Membrane stabilization through phosphatidylcholine synthesis
  • Reduction of glutamate release (pro-inflammatory neurotransmitter)
  • Antioxidant effects by decreasing free radical production
  • Anti-inflammatory properties via modulation of microglial activity and NF-κB inhibition
  • Reduction of inflammatory cytokine production 3

Critical caveat: Despite decades of research, there remains no adequate description of the precise pharmacological mechanism(s) of action 2.

Clinical Indications and Evidence

Acute Ischemic Stroke: NOT RECOMMENDED

The highest quality evidence definitively shows no benefit. The International Citicoline Trial on Acute Stroke (ICTUS) enrolled 2,298 patients with moderate to severe ischemic stroke within 24 hours of onset. This large European multicenter trial was stopped prematurely in 2011 for futility, showing no difference in 90-day outcomes (OR 1.03,95% CI 0.86-1.25, P=0.364) 1.

While earlier smaller trials and meta-analyses suggested potential benefit, particularly in patients not receiving rtPA 4, the definitive ICTUS trial supersedes these findings. The AHA/ASA guidelines explicitly state that citicoline trials "did not demonstrate treatment efficacy" 1.

Glaucoma: POTENTIALLY BENEFICIAL

Emerging evidence supports citicoline use in open-angle glaucoma. A 2025 randomized, double-blind study demonstrated that citicoline oral solution (500 mg/day) for 12 months significantly improved:

  • PERG P50-N95 and VEP N75-P100 amplitudes (p < 0.01)
  • PERG P50 and VEP P100 implicit times
  • Retinocortical Time (RCT)
  • Visual field mean deviation

These improvements correlated with enhanced retinal function and changes in visual pathway connectivity on DTI-MRI 5. This represents the most recent high-quality evidence supporting citicoline use in a specific neurological condition.

Cognitive Impairment: LIMITED EVIDENCE

For mild vascular cognitive impairment and age-related memory decline, citicoline shows some promise in slowly advancing neurodegenerative conditions 2. However, the evidence base is substantially weaker than for glaucoma, consisting primarily of observational studies and smaller trials 6.

Traumatic Brain Injury: NOT RECOMMENDED

Similar to stroke, large pivotal trials have revealed no benefits in traumatic brain injury 2.

Dosing Regimens

Note: The FDA drug label information provided 7 appears to be for cimetidine (an H2 blocker), not citicoline—this is a data error and should be disregarded.

Based on clinical trial data:

  • For glaucoma: 500 mg/day orally 5
  • Historical stroke trials (not recommended): 500-2000 mg/day, with 500 mg appearing optimal in early studies 8
  • Duration: 6-12 months for chronic conditions 5, 6

Safety Profile

Citicoline demonstrates excellent safety and tolerability. In a large surveillance study of 4,191 acute stroke patients, only 0.73% experienced side effects, most commonly:

  • Nervous system symptoms (21.6% of adverse events)
  • Gastrointestinal symptoms (13.5% of adverse events)

No drug-related serious adverse events or deaths were reported 9, 8.

Clinical Bottom Line

Do not use citicoline for acute ischemic stroke or traumatic brain injury—the highest quality evidence shows no benefit on mortality, morbidity, or functional outcomes. Consider citicoline (500 mg/day orally) for open-angle glaucoma based on recent positive trial data showing functional improvements and enhanced neural conduction. For other indications, evidence remains insufficient to support routine use.

The disconnect between promising preclinical data and negative clinical trials likely reflects inadequate understanding of the drug's pharmacodynamics and the possibility that rapid catabolism limits efficacy in acute conditions 2.

References

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.